Taiwan's Aprinoia Therapeutics raises $11m co-led by KTB Network, DCI Partners

Aprinoia Therapeutics

Taiwan-based Aprinoia Therapeutics Inc, a clinical-stage neuroscience biotech company, said it has completed its $11 million Series B funding round co-led by Korea’s KTB Network and Japan’s DCI Partners.

The company, which focuses on novel targets for neurodegenerative diseases, also caught the interest of China’s ShangPharma Investment Group and Taiwan’s Taian Technologies, which participated in the funding round.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter